Amyloid-β and treatment opportunities for Alzheimer's disease

Journal of Alzheimer's Disease

Volumn 2, Issue 3-4, 2000, Pages 231-259

  Sabbagh, Marwan N ^b,c   Galasko, Douglas ^b,c   Koo, Edward ^a,b,c   Thal, Leon J ^b,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b SUN HEALTH RESEARCH INSTITUTE   (United States)

^c VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4' IODOESORUBICIN; ALPHA SECRETASE INHIBITOR; AMMONIUM CHLORIDE; AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; BAFILOMYCIN A1; BREFELDIN A; CALCIUM; CALCIUM CHANNEL BLOCKING AGENT; CALPASTATIN; CALRETININ; CARBAMAZEPINE; COLCHICINE; CYTOCHALASIN D; DIZOCILPINE; ENZYME INHIBITOR; ESTRADIOL; FREE RADICAL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEMBRANE METALLOENDOPEPTIDASE; MEPACRINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NIFEDIPINE; NIMODIPINE; OMEGA CONOTOXIN; RIFAMPICIN; TACRINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VERAPAMIL; [1 [(1 FORMYL 2 PHENYLETHYL)CARBAMOYL] 2 METHYLPROPYL]CARBAMIC ACID BENZYL ESTER;

ALZHEIMER DISEASE; APOPTOSIS; ARTICLE; CALCIUM HOMEOSTASIS; COGNITION; HUMAN; INFLAMMATION; MEMBRANE DAMAGE; NEUROTOXICITY; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN DEPLETION; PROTEIN SYNTHESIS; SENILE PLAQUE;

EID: 0034489963     PISSN: 13872877     EISSN: None     Source Type: Journal    
DOI: 10.3233/JAD-2000-23-405     Document Type: Article

References (273)

1. Induction of amyloid processing protein mRNA after heat shock in cultured human lymphoblastoid cells
2. A randomized controlled trial of prednisone in Alzheimer's disease
3. The structure of the presenilin 1 (S182) gene identification of six novel mutations in early onset AD families
4. Unusual phenotypic alteration of beta amyloid precursor protein (betaAPP) maturation by a new Val-715→Met betaAPP-770 mutation responsible for probable early-onset Alzheimer's disease
5. Presenilins: Molecular switches between proteolysis and signal transduction
6. Long amyloid beta-protein secreted from wild-type human neuroblastoma IMR-32 cells
7. Lack of apolipoprotein E dramatically reduces amyloid β-peptide deposition
8. Mechanisms of excitotoxicity in neurologic diseases
9. Vitamin E protects nerve cells from amyloid beta protein toxicity
10. Hydrogen peroxide mediates amyloid beta protein toxicity
11. Clinicopathologic studies in cognitively healthy aging and Alzheimer's disease: Relation of histologic markers to dementia severity, age, sex, and apolipoprotein E genotype
12. Apolipoprotein E allele epsilon 4 is linked to increased deposition of the amyloid bb-peptide (Abb) in cases with or without Alheimer's disease
13. Familial Alzheimer's disease-linked presenilin 1 variants elevate Abetal-42/l-40 ratio in vitro and in vivo
14. A role for apolipoprotein E, apolipoprotein A-1, and low density lipoprotein receptors in cholesterol transport during regeneration and remyelination of the rat sciatic nerve
15. Pathology of Alzheimer's disease
16. Neural apoptosis
17. Strategies for neuroprotection with glutamate antagonists. Extrapolating from evidence taken from the first stroke and head injury studies
18. L-deprenyl in the treatment of mild dementia of the Alzheimer type: Results of a 15-month trial
19. β-amyloid fibrils induce tau phosphorylation and loss of microtubule binding
20. Modulation of A beta adhesiveness and secretase site cleavage by zinc
21. Vitamin E as an antioxidant/free radical scavenger against amyloid beta-peptide-induced oxidative stress in neocortical synaptosomal membranes and hippocampal neurons in culture: Insights into Alzheimer's disease
22. Release of excess amyloid β protein from a mutant beta protein precursor
23. Protein phosphorylation regulates secretion of Alzheimer β/A4 amyloid protein precursor
24. Fibrillogenesis in Alzheimer's disease of amyloid beta peptides and apolipoprotein E
25. Lysosomal abnormalities in degenerating neurons link neuronal compromise to senile plaque development in Alzheimer disease
26. Lysosomal hydrolases of different classes are abnormally distributed in Alzheimer brain
27. Lysosomal proteinase antigens are prominently localized within senile plaques of Alzheimer's disease: Evidence for a neuronal origin
28. Early-onset Alzheimer's disease caused by a mutation at codon 717 of the β-amyloid precursor protein gene
29. Glucose deprivation elicits neurofibrillary tangle-like antigenic changes in hippocampal neurons: Prevention by NGF and bFGF
30. Aqueous dissolution of Alzheimer's disease Abeta amyloid deposits by biometal depletion
31. Evidence that the 42- and 40-amino acid forms of amyloid β protein are generated from the β-amyloid precursor protein by different protease activities
32. Mutation of the b amyloid precursor protein in familial Alzheimer's disease increase β protein production
33. Excessive production of amyloid beta-protein by peripheral cells of symptomatic and presymptomatic patients carrying the Swedish familial Alzheimer disease mutation
34. Activation of metabotropic glutamate receptors protects cultured neurons against apoptosis induced by β-amyloid peptide
35. Apolipoprotein E, survival in Alzheimer's disease patients, and the competing risks of death and Alzheimer's disease
36. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families
37. Nonsteroidal anti-inflammatory drugs and the risk of Alzheimer's disease
38. A potential role for apoptosis in neurodegeneration and Alzheimer's disease
39. Possible role of apoptosis in Alzheimer's disease
40. Image analysis of β-amyloid load in Alzheimer's disease and relation to dementia severity
41. Evaluation of multiple doses of milacemide in the treatment of senile dementia of the Alzheimer's type
42. Inhibition of protein phosphatase 1 stimulates secretion of Alzheimer amyloid precursor protein
43. Enhanced processing of APP induced by 1L-1β can be reduced by indomethacin and nordihydroguaiaretic acid
44. A firm base for drug development
45. Relationship between apolipoprotein E and the amyloid deposits and dystrophic neurites of Alzheimer's disease
46. Protein topology of presenilin 1
47. Excitatory amino acid receptors and neurodegeneration
48. Changes in brain gene expression shared by scrapie and Alzheimer disease
49. Does amyloid precede paired helical filaments in the senile plaque? A study of 15 cases with graded intellectual status in aging and Alzheimer disease
50. Milacemide: A placebo-controlled study in senile dementia of the Alzheimer type
51. A new pathogenic mutation in the APP gene (1716V) increases the relative proportion of A beta 42(43)
52. 1-Antichymotrypsin regulates Alzheimer β-amyloid peptide fibril formation
53. Cleavage of amyloid β-peptide during conservative processing of its precursor
54. Potentially amyloidogenic, carboxyl-terminal derivative of the amyloid precursor protein
55. Apolipoprotein E is a kinetic but not a thermodynamic inhibitor of amyloid formation: Implications for the pathogenesis and treatment of Alzheimer's disease
56. Candidate gamma-secretases in the generation of the carboxyl terminus of Alzheimer's disease beta A4 amyloid: Possible involvement of cathepsin D
57. Distinct secretases, a cysteine protease and a serine protease, generate the C termini of amyloid beta-proteins Abeta1-40 and Abeta1-42, respectively
58. Apoptosis-/mediated neurotoxicity induced by chronic application of beta amyloid fragment
59. Biochemistry of Alzheimer's disease amyloid plaques
60. Phagocytosis and deposition of vascular β-amyloid in rat brains injected with Alzheimer β-amyloid
61. Alzheimer's disease: Clinical features and differential diagnosis
62. Increased expression of beta amyloid precursor protein and microtubule associated protein tau during the differentiation of murine embryonal carcinoma cells
63. Synthesis, aggregation, and neurotoxicity of the Alzheimer's Abeta1 1-42 amyloid peptide and its isoaspartyl isomer
64. 2+ influx
65. Alzheimer-type neuropathology in transgenic mice overexpressing V717F β-amyloid precursor protein
66. Regulated cleavage of the Alzheimer amyloid precursor protein: Molecular and cellular basis
67. A beta-peptide length and apolipoprotein E genotype in Alzheimer's disease
68. Regional variation in the distribution of apolipoprotein E and A beta in Alzheimer's disease
69. Aging renders the brain vulnerable to amyloid beta-protein neurotoxicity
70. Cholinesterase inhibitors do more than inhibit cholinesterase
71. Does Alzheimer disease tilt the scales of amyloid degradation versus accumulation
72. Expression of beta amyloid protein precursor mRNAs: Recognition of a novel alternatively spliced form and quantitation in Alzheimer disease during PCR
73. Processing of the amyloid protein precursor to potentially amyloidogenic carboxyl-terminal derivatives
74. Characterization and chromosomal localization of a cDNA encoding brain amyloid of Alzheimer's disease
75. The impact of different presenilin 1 and presenilin 2 mutations on amyloid deposition, neurofibrillary changes and neuronal loss in the familial Alzheimer's brain: Evidence for other phenotype modifying factors
76. Amyloid β protein (Aβ) in Alzheimer's disease brain: Biochemical and immunocytochemical analysis with antibodies specific for forms ending at Aβ40 or Aβ42(43)
77. Induction of beta-amyloid precursor protein isoform mRNAs by bFGF in astrocytes
78. Apolipoprotein Ee4 and cerebral hemorrage associated with amyloid angiopathy
79. Clinical results with nimodipine in Alzheimer disease
80. β-amyloid peptide and a 3-kDa fragment are derived by distinct cellular mechanisms
81. Amyloid β-peptide is produced by cultured cells during normal metabolism
82. The Swedish mutation causes early-onset Alzheimer's disease by beta-secretase cleavage within the secretory pathway
83. Targeting of cell-surface β-amyloid precursor protein to lysosomes: Alternative processing into amyloid-bearing fragments
84. Apolipoprotein E is localized to the cytoplasm of human cortical neurons: A light and electron microscopic study
85. Apolipoprotein E is present in hippocampal neurons without neurofibrillary tangles in Alzheimer's disease and in age-matched controls
86. Effects of apolipoprotein E, B-very low density lipoproteins, and cholesterol on the extension of neurites by rabbit dorsal root ganglion neurons in vitro
87. In search of γ-secretase
88. Direct evidence of oxidative injury produced by the Alzheimer's β-amyloid peptide (1-40) in cultured hippocampal neurons
89. Intracellular biology of Alzheimer's disease amyloid beta peptide
90. Neuronal death
91. β-amyloid inhibition of MTT reduction is not mimicked by inhibitors of mitochondrial respiration
92. Alzheimer pathology of patients carrying apolipoprotein E epsilon 4 allele
93. Lazabemide (Ro 19-6327), a reversible and highly sensitive MAO-B inhibitor: Preclinical and clinical findings
94. A model for beta-amyloid aggregation and neurotoxicity based on free radical generation by the peptide: Relevance to Alzheimer disease
95. Inhibition of β-amyloid formation identifying proteolytic precursors and subcellular site of catabolism
96. Blockade of glutamate excitotoxicity and its clinical applications
97. Expression of human apolipoprotein E reduces amyloid-beta deposition in a mouse model of Alzheimer's disease
98. Low density lipoprotein receptor-related protein mediates apolipoprotein E-dependent neurite outgrowth in a central nervous system-derived neuronal cell line
99. Correlative memory deficits, Aβ elevation, and amyloid plaques in transgenic mice
100. Idenitication of a novel aspartic protease (Asp 2) as beta-secretase
101. The role of β-amyloid in the development of Alzheimer's disease
102. Identification of the major Ab1-42 degrading catabolic pathway in brain parenchyma: Suppression leads to biochemical and pathological deposition
103. Visualization of Aβ42(43) and Aβ40 is senile plaques with end-specific Aβ monoclonal: Evidence that an initially deposited species is Aβ42(43)
104. Quantitative measurement of alternatively spliced amyloid precursor protein mRNA expression in Alzheimer's disease and normal brain by S1 nuclease protection analysis
105. Estrogen regulates metabolism of Alzheimer amyloid beta precursor protein
106. The carboxy terminus of the β amyloid protein is critical for the seeding of amyloid formation: Implications for the pathogenesis of Alzheimer's disease
107. Seeding one-dimensional crystallization of amyloid: A pathogenic mechanism in Alzheimer's disease and scrapie
108. Diffuse senile plaques occur commonly in the cerebellum in Alzheimer's disease
109. Relation of neuronal APP-751/APP-695 mRNA ratio and neuritic plaque density in Alzheimer's disease
110. Intracerebroventricular infusion of nerve growth factor in three patients with Alzheimer's disease
111. Cerebral microvasculature and immunological factors in Alzheimer's disease
112. The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor
113. Diagnosis of Alzheimer's disease
114. Calpain inhibitor I decrease beta A4 secretion from human embryonal kidney cells expressing beta-amyloid precursor protein carrying the APP670/671 double mutation
115. Long-term tacrine treatment: Effect on nursing home placement
116. Cell-type and amyloid precursor protein-type specific inhibition of Aβ releaseby Bafilomycin A1 a selective inhibitor of vacuolar ATPases
117. Precursor of amyloid protein in Alzheimer's disease undergoes fast anterograde transport
118. Alzheimer-associated presenilins 1 and 2: Neuronal expression in brain and localization to intracellular membranes in mammalian cells
119. An in vivo model for the neurodegenerative effects of beta-amyloid and protection by substance P
120. In vivo neurotoxicity of beta amyloid (beta 1-40) and the beta (25-35) fragment
121. The apolipoprotein E allele ee4 does not correlate with the number of senile plaques or neurofibrillary tangles in patients with Alzheimer's disease
122. Cell death in Alzheimer's disease evaluated by DNA fragmentation in situ
123. Regulation of apolipoprotein E gene expression after injury of the rat sciatic nerve
124. A familial Alzheimer's disease locus on chromosome 1
125. Candidate gene for the chromosome 1 familial Alzheimer's disease locus
126. Colchicine treatment of AA amyloidosis of familial Mediterranean fever: An analyisis of factors affecting outcome
127. 25-35 peptide-mediated neurotoxicity in rat hippocampal cultures
128. Apoptosis is induced by β-amyloid in cultured central nervous system neurons
129. β-amyloid neurotoxicity requires fibril formation and is inhibited by Congo red
130. Cholesterol transport protein with expanding role in cell biology
131. Partial restoration of choline acetyltransferase activities in aging and AF64A-lesioned rat brains by vitamin E
132. Is the pattern of nerve cell loss in aging and Alzheimer's disease a real, or only an apparent selectivity
133. L-deprenyl and physostigmine for the treatment of Alzheimer's disease
134. 2+ deregulation, and cytoskeletal pathology
135. Evidence for excitoprotective and intraneuronal calcium-regulating roles for secreted forms of the β-amyloid precursor protein
136. Different amyloidogenic peptides share a similar mechanism of neurotoxicity involving reactive oxygen species and calcium
137. Beta-amyloid precursor protein metabolites and loss of neuronal calcium homeostasis in Alzheimer's disease
138. Beta-amyloid peptides destabilize calcium homeostasis and render human cortical neurons vulnerable to excitotoxicity
139. Beta amyloid precursor protein and Alzheimer's disease: The peptide plot thickens
140. Calcium-destabilizing and neurodegenerative effects of aggregated beta-amyloid peptide are attenuated by basic FGF
141. The apolipoprotein e4 allele in patients with Alzheimer's disease
142. Brain inflammation in Alzheimer's disease and the therapeutic implications
143. Anti-inflammatory drugs and Alzheimer's disease
144. Anti-inflammatory drugs in the fight against Alzheimer's disease
145. Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's Disease: A review of 17 epidemiologic studies
146. Activation of microglial cells by β-amyloid protein and interferon γ
147. Caspases find a new place to hide
148. Interaction of the anthracycline 4′-iodo-4′-deoxydoxorubicin with amyloid fibrils: Inhibition of amyloidogenesis
149. Mounting evidence for the involvement of copper and zinc in Alzheimer's disease
150. Nimodipine in the treatment of probable Alzheimer's disease. Results of two multicentre trials
151. Cerebral amyloid deposition and diffuse plaques in "normal" aging: Evidence for presymptomatic and very mild Alzheimer's disease
152. Reduction of beta-amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer's disease
153. Entorhinal cortex beta-amyloid load in individuals with mild cognitive impairment
154. A pathogenic mutation for probable Alzehimers disease in the APP N-terminus of the beta amyloid
155. Estrogen replacement therapy for treatment of mild to moderate Alzheimer Disease
156. Identification of the multicatalytic enzyme as a possible γ-secretase for the amyloid precursor protein
157. Lysosomal processing of amyloid precursor protein to A beta peptides: A distinct role for cathepsin S
158. A mutation in the amyloid precursor protein associated with hereditary Alzheimers disease
159. Influence of the apolipoprotein E genotype on amyloid deposition and neurofibrillary tangle formation in Alzheimer's disease
160. Caspase-12 mediates endoplasmic-reticulum-specific apoptosis and cytotoxicity by amyloid-β
161. Alpha-tocopherol supports the survival and neurite extension of neurons cultured from various regions of fetal rat brain
162. Correlation between elevated levels of amyloid betapeptide in the brain and cognitive decline
163. Cerebrospinal fluid levels of amyloid beta-protein in Alzheimer's disease: Inverse correlation with severity of dementia and effect of apolipoprotein E genotype
164. Release of Alzheimer amyloid precursor derivatives stimulated by activation of muscarinic acetylcholine receptors
165. Apolipoprotein E polymorphism influences not only cerebral senile plaque load but also Alzheimer-type neurofibrillary tangle formation
166. Apolipoprotein E isoforms and the development of low and high Braak stages of Alzheimer's disease-related lesions
167. NGF and the treatment of Alzheimer's disease
168. The Alzheimer amyloid precursor protein Identification of a stable intermediate in the biosynthetic/degradative pathway
169. The β-amyloid protein precursor of Alzheimer's disease has soluble derivatives found in human brain and cerebrospinal fluid
170. Microglial cells internalize aggregates of the Alzheimer's disease amyloid beta-protein via a scavenger receptor
171. Linkage studies in familial Alzheimer's disease: Evidence for chromosome 19 linkage
172. Microangiopathy and the colocalization of heparan sulfate proteoglycan with amyloid in senile plaques of Alzheimer's disease
173. Cultured GABA-immunoreactive neurons are resistant to toxicity induced by β-amyloid
174. Calretinin-immunoreactive neurons are resistant to β-amyloid toxicity in vitro
175. In vitro aging of beta-amyloid protein cause peptide aggregation and neurotoxicity
176. Apolipoprotein E genotype and amyloid load in Alzheimer disease and control brains
177. Apolipoprotein E polymorphism and Alzheimer's disease
178. Sulfated glycosaminoglycans and dyes attenuate the neurotoxic effects of β-amyloid in rat PC12 cells
179. The potential of BACE inhibitors for Alzheimer's therapy
180. Molecular mapping of Alzheimer-type dementia in Down's syndrome
181. Mutant genes in familial Alzheimer's disease and transgenic models
182. Degradation of amyloid beta-protein by a serine protease-alpha2-macroglobulin complex
183. Expression of the low-affinity nerve growth factor receptor enhances β-amyloid peptide toxicity
184. Multiple, diverse senile plaque-associated proteins are ligands of an apolipoprotein E receptor, the alpha 2-macroglobulin receptor/low-density-lipoprotein receptor-related protein
185. Nerve and epidermal growth factors induce the release of the Alzheimer amyloid precursor protein from PC12 cell cultures
186. The role of amyloid β-protein in Alzheimer's disease
187. Melatonin as a pharmacological agent against neuronal loss in experimental models of Huntington's disease, Alzheimer's disease, and parkinsonism
188. Beta A4 amyloid protein deposition in brain after head trauma
189. Familial Alzheimer's disease in kindreds with missense mutations in a gene on chromosome 1 related to the Alzheimer's disease type 3 gene
190. A clinical trial of indomethacin in Alzheimer's disease
191. Complement activation of β-amyloid in Alzheimer disease
192. Morphological and biochemical analyses of amyloid plaque core proteins purified from Alzheimer disease brain tissue
193. Report of the committee on genetic constitution of chromosome 19 human gene mapping 11
194. ApoE is a major susceptibility gene for Alzheimer's disease
195. Distribution of beta/A4 protein and amyloid precursor protein in hereditary cerebral hemorrage with amyloidosis-Dutch type and Alzheimer's disease
196. Glycosaminoglycans and sulphated polyanions attenuate the neurotoxic effects of β-amyloid
197. A controlled trial of selegiline, alpha-tocopherol or both as treatment for Alzheimer's disease
198. Association of apolipoprotein E allele e4 with late-onset familial and sporadic Alzheimer's disease
199. A double-blind, placebo-controlled trial of diclofenac/ misoprostol in Alzheimer's disease
200. Genetic linkage evidence for a familial Alzheimer's disease locus on chromosome 14
201. Immunization with amyloid-b attenuates Alzheimer-disease-like pathology in the PDAPP mouse
202. Fibroblasts from carriers of familial AD linked to chromosome 14 show increased A production
203. Secreted amyloid β-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease
204. Increased amyloid β peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late onset Alzheimer's disease
205. A double-blind crossover pilot study of l-deprenyl (selegiline) combined with cholinesterase inhibitor in Alzheimer's disease
206. The regulation of amyloid β protein precursor secretion and its modulatory role in cell adhesion
207. Amyloid peptides are toxic via a common oxidative mechanism
208. Amyloid beta protein precursor is possibly a heparan sulfate proteoglycan core protein
209. The effects of milacemide on item and source memory
210. Mechanism of prevention of amyloid beta protein aggregation by transthyretin and apolipoprotein E
211. Physiological production of the beta-amyloid protein and the mechanism of Alzheimer's disease
212. Alzheimer's disease: A central role for amyloid
213. Missense of the membrane
214. Translating cell biology into therapeutic advances in Alzheimer's disease
215. Levels of alpha- and beta-secretase cleaved amyloid precursor protein in cerebrospinal fluid of Alzheimer's disease patients
216. Amyloid beta protein (A beta) removal by neuroglial cells in culture
217. Inhibition of PCI2 cell redox activity is a specific, early indicator of the mechanism of beta-amyloid-mediated cell death
218. Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease
219. Expression of beta amyloid precursor protein in reactive astrocytes following neuronal damage
220. Purification and cloning of amyloid precursor protein β-secretase from human brain
221. Cellular mechanisms of the beta-amyloid production and secretion
222. β-amyloid precursor protein cleavage by a membrane bound protease
223. Role of the β-amyloid protein in Alzheimer's disease
224. Free radical damage, iron, and Alzheimer's disease
225. Radical Ageing in Alzheimer's disease
226. Carbonyl-related posttranslational modification of neurofilament protein in the neurofibrillary pathology of Alzheimer's disease
227. Nerve injury stimulates the secretion of apolipoprotein E by non-neuronal cells
228. Heparan Sulfate proteoglycan in diffuse plaques of hippocampus but not of cerebellum in Alzheimer's disease brain
229. Monoclonal antibodies inhibit in vitro fibrillar aggregation of the Alzheimer beta-amyloid peptide
230. Long term acetyl-L-carnitine treatment in Alzheimer's disease
231. The link between heart disease, cholesterol and Alzheimer's disease: A review
232. Genetic evidence for a novel familial AD locus on chromosome 14
233. Apolipoprotein E: High avidity binding to β amyloid and increased frequency of type 4 allele in late onset familial Alzhiemer's disease
234. Binding of human apolipoprotein E to synthetic amyloid β peptide: Isoform-specific effects and implications for late-onset Alzheimer disease
235. Presenilin is required for activity and nuclear access of Notch in Drosophila
236. Immunohistochemical evidence for apoptosis in Alzheimer's disease
237. An increased percentage of long amyloid β protein secreted by familial amyloid β protein precursor (βAPP717) mutants
238. Microglial activation resulting from CD40-CD40L interaction after beta-amyloid stimulation
239. The ApoEepsilon 4 allele and the risk of Alzheimer's disease among African Americans, whites, and hispanics
240. Molecular genetics of Alzheimer's disease and the amyloid beta peptide precursor gene
241. Clinical implications for basic research: A promising animal model for Alzheimer's disease
242. Cognitive effects of L-deprenyl in Alzheimer's disease
243. Presence of soluble amyloid beta-peptide precedes amyloid plaque formation in Down's syndrome
244. 1-year multicenter placebo controlled study of acetyl-l-carnitine in patients with Alzheimer's disease
245. Excitatory amino acids in health and disease
246. Arrest of β-amyloid fibril formation by a pentapeptide ligand
247. Generation of Alzheimer amyloid β peptide through nonspecific proteolysis
248. Concentrations of alpha-tocopherol and its quinone derivative in cerebrospinal fluid from patients with vascular dementia of the Binswanger type and Alzheimer type dementia
249. Rifampicin prevents the aggregation and neurotoxicity of amyloid β protein in vitro
250. Inhibition of amyloid beta protein aggregation and neurotoxicity by rifampicin. Its possible function as a hydroxyl radical scavenger
251. Presenilins and Alzheimer's disease
252. Mapping of a gene predisposing to early-onset Alzheimer's disease to chromosome 14q243
253. Betasecretase cleavage in Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE
254. Solvent effects on beta protein toxicity in vivo
255. Identification, biogenesis and localization of precursors of Alzheimer's disease A4 amyloid protein
256. Lipoproteins, neurobiology, and Alzheimer's disease: Structure and function of apolipoprotein E
257. 2+ channel blockers attenuate β-amyloid peptide toxicity to cortical neurons in culture
258. Neurotoxicity of Aβ amyloid protein in vitro is not altered by calcium channel blockade
259. Memantine in severe dementia: Results of the 9M-Best study (Benefit and efficacy in severely demented patients during treatment with memantine
260. Lack of long-term effects after β-amyloid protein injections in rat brain
261. Reversible Schwann cell hyperplasia and sprouting of sensory and sympathetic neurites after intraventricular administration of nerve growth factor
262. Occurrence of neuropathological changes and dementia of Alzheimer's disease in Down's syndrome
263. Apolipoprotein E binding to soluble Alzheimer's beta-amyloid
264. Two transmembrane aspartates in presenilin-1 required for presenilin endoproteolysis and gamma-secretase activity
265. A substrate-based diflouro ketone selectively inhibits Alzheimer's gamma secretase activity
266. Diffuse type of senile plaques in the brains of Alzheimer-type dementia
267. Diffuse plaques associated with astroglial amyloid beta protein, possibly showing a disappearing stage of senile plaques
268. Membrane-anchored aspartyl protease with Alzheimer's disease β-secretase activity
269. Neurogenic phenotypes and altered Notch processing in Drosophila presenilin mutants
270. Genomic organization of the human amyloid beta-protein precursor gene
271. The 717Val-Ile substitution in the amyloid precursor protein is associated with familial AD regardless of the ethnic group
272. Evidence that Aβ42 is the real culprit in Alzheimer's disease
273. Therapeutic potential of neurotrophic factors for neurological disorders